miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International Journal of Molecular Medicine

• Publication date

  2015-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/ijmm.2015.2076PMID 25605429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease.

  2014cited by this paper
• A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?

  2013cited by this paper
• Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet.

  2012cited by this paper
• Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease.

  2012cited by this paper
• Lipotoxicity in HepG2 cells triggered by free fatty acids.

  2011cited by this paper
• Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin.

  2011cited by this paper
• Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

  2011cited by this paper
• Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice

  2010cited by this paper
• Differential expression of microRNAs in mouse liver under aberrant energy metabolic status[S]

  2009cited by this paper
• Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH.

  2009cited by this paper
• JNK1-dependent PUMA Expression Contributes to Hepatocyte Lipoapoptosis*

  2009cited by this paper
• MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease.

  2009cited by this paper
• Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression

  2008cited by this paper
• Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase

  2008cited by this paper
• MicroRNAs and cancer: past, present, and potential future

  2008cited by this paper
• Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients

  2007cited by this paper
• [An introduction of strategies for the management of nonalcoholic fatty liver disease (NAFLD) recommended by Asia Pacific Working Party on NAFLD].

  2007cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006cited by this paper
• Encountering MicroRNAs in Cell Fate Signaling

  2005cited by this paper
• Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study

  2005cited by this paper
• Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity

  2004cited by this paper
• MicroRNAs and the regulation of cell death.

  2004cited by this paper
• Hepatic steatosis and type 2 diabetes mellitus

  2002cited by this paper
• Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.

  2001cited by this paper
• Nutritional and Metabolic Considerations in the Etiology of Nonalcoholic Steatohepatitis

  2001cited by this paper
• Current perspectives on statins.

  2000cited by this paper
• Unbound free fatty acid levels in human serum.

  1995cited by this paper
• Modulation of the enzymic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase systems involving reversible phosphorylation: a review.

  1987cited by this paper
• Phosphorylation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and modulation of its enzymic activity by calcium-activated and phospholipid-dependent protein kinase.

  1985cited by this paper

• LncRNA TUG1 promotes hepatic lipid accumulation by targeting the miR-29a-3p/SREBP-2/HMGCR axis in MAFLD

  2026cites this paper
• Investigating the Diagnostic Utility of LncRNA GAS5 in NAFLD Patients

  2025cites this paper
• Circulating microRNAs as potential non-invasive biomarkers for diagnosis and severity assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease: a case–control study

  2025cites this paper
• MicroRNA-21 is a potential therapeutic agent targeting Tgfbi and mitigating high-fat-diet-induced liver disease and cancer

  2025cites this paper
• Identification of Circulating MiR-4651 as Novel Biomarker for Metabolic Dysfunction–Associated Steatotic Liver Disease

  2025cites this paper
• Non-coding RNAs in Wilson's Disease: Plausible drivers of hepatic symptom heterogeneity.

  2025cites this paper
• microRNA-21 promotes dysregulated lipid metabolism and hepatocellular carcinoma

  2025cites this paper
• From fatty liver to fibrosis: the impact of miRNAs on NAFLD and NASH

  2025cites this paper
• The use of circulating miRNAs for the diagnosis, prognosis, and personalized treatment of MASLD

  2025cites this paper
• Non-coding RNAs in alcohol-associated liver disease

  2025cites this paper
• Molecular Landscape and Diagnostic Model of MASH: Transcriptomic, Proteomic, Metabolomic, and Lipidomic Perspectives

  2025cites this paper
• An oligosaccharide isolated from Rosa canina ameliorates lipid profile and liver damage in MASLD modeled rabbits: in vivo and in silico studies

  2025cites this paper
• A Class of MicroRNAs as Diagnostic Biomarkers and Therapeutic Strategies in Non-Alcoholic Fatty Liver Disease.

  2025cites this paper
• MicroRNA and Protein Biomarkers of Intestinal Permeability in the Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2025cites this paper
• Molecular Insights of Nonalcoholic Fatty Liver Disease Pathogenesis

  2024cites this paper
• Non-Invasive Biomarkers and Breath Tests for Diagnosis and Monitoring of Chronic Liver Diseases

  2024cites this paper
• Regulatory, diagnostic, and therapeutic roles of microRNAs in chronic liver diseases.

  2024cites this paper
• Integrating larval zebrafish model and network pharmacology for screening and identification of edible herbs with therapeutic potential for MAFLD: A promising drug Smilax glabra Roxb.

  2024cites this paper
• miR-21: A therapeutic target for delaying severe liver disease and hepatocellular carcinoma in high-fat-diet-fed mice

  2024cites this paper
• Exosome prospects in the diagnosis and treatment of non-alcoholic fatty liver disease

  2024cites this paper
• Evaluation of the diagnostic role of circulating miR-16, miR-10b, and miR-21 expression in patients with nonalcoholic fatty liver disease

  2024cites this paper
• MicroRNA-2285f regulates milk fat metabolism by targeting MAP2K2 in bovine mammary epithelial cells.

  2024cites this paper
• A comprehensive review of miR-21 in liver disease: Big impact of little things.

  2024cites this paper
• MiRNA-21-5p induces chicken hepatic lipogenesis by targeting NFIB and KLF3 to suppress the PI3K/AKT signaling pathway.

  2024cites this paper
• Circulating miR-206, miR-181b, and miR-21 as promising biomarkers in hypothyroidism and their relationship to related hyperlipidemia and hepatic steatosis

  2024cites this paper
• MicroRNAs as Biomarkers and Therapeutic Targets for Nonalcoholic Fatty Liver Disease: A Narrative Review.

  2023cites this paper
• 6-Gingerol regulates triglyceride and cholesterol biosynthesis to improve hepatic steatosis in MAFLD by activating the AMPK-SREBPs signaling pathway.

  2023cites this paper
• Regulation of hepatic lipid metabolism by intestine epithelium-derived exosomes

  2023cites this paper
• miRNA – molecular biomarkers in non-alcoholic fatty liver disease: potential targets in nutritional interventions

  2023cites this paper
• Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease

  2023cites this paper
• Swimming exercise ameliorates insulin resistance and nonalcoholic fatty liver by negatively regulating PPARγ transcriptional network in mice fed high fat diet

  2023cites this paper
• Functional analysis of differentially expressed circular RNAs in sheep subcutaneous fat

  2023cites this paper
• MicroRNAs and Nonalcoholic Steatohepatitis: A Review

  2023cites this paper
• Effect of diet and genotype on the miRNome of mice with altered lipoprotein metabolism

  2023cites this paper
• Insight into the Inter-Organ Crosstalk and Prognostic Role of Liver-Derived MicroRNAs in Metabolic Disease Progression

  2023influential citation
• Ficus deltoidea Leaf Alters Oxidative Stress, Protein Homeostasis and Ubiquitin-Proteasome Pathways in Fatty Acid-Induced Cell Line

  2023cites this paper
• Serum microRNA Levels as a Biomarker for Diagnosing Non-Alcoholic Fatty Liver Disease in Chinese Colorectal Polyp Patients

  2023cites this paper
• "MiR-7 controls cholesterol biosynthesis through posttranscriptional regulation of DHCR24 expression".

  2023cites this paper
• Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease

  2023cites this paper
• The critical role of microRNA-21 in Non-alcoholic Fatty Liver Disease pathogenesis.

  2023cites this paper
• Nonalcoholic Fatty Liver Disease and MicroRNAs: A Weighty Consideration

  2023cites this paper
• Circulating microRNAs Are Associated With Metabolic Markers in Adolescents With Hepatosteatosis

  2022cites this paper
• Long non-coding RNA GAS5 contributes to the progression of nonalcoholic fatty liver disease by targeting the microRNA-29a-3p/NOTCH2 axis

  2022cites this paper
• Research Progress of miR-21 in Non-Alcoholic Fatty Liver Disease

  2022cites this paper
• Cardiac Metabolism and MiRNA Interference

  2022cites this paper
• Investigating microRNAs to Explain the Link between Cholesterol Metabolism and NAFLD in Humans: A Systematic Review

  2022influential citation
• Role of microRNA in Endocrine Disruptor-Induced Immunomodulation of Metabolic Health

  2022cites this paper
• MicroRNA-874 targets phosphomevalonate kinase and inhibits cancer cell growth via the mevalonate pathway

  2022cites this paper
• The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC

  2022cites this paper
• Moringa oleifera Improves MAFLD by Inducing Epigenetic Modifications

  2022cites this paper
• Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease

  2022cites this paper
• Loperamide Induces Excessive Accumulation of Bile Acids in the Liver of Mice with Different Diets.

  2022cites this paper
• The Role of MicroRNAs in Hyperlipidemia: From Pathogenesis to Therapeutical Application

  2022cites this paper
• Study on the Factors Related to Cholesterol Metabolism Pathway and Non-Alcoholic Fatty Liver Disease

  2022cites this paper
• Study on the Factors Related to Cholesterol Metabolism Pathway and Non-Alcoholic Fatty Liver Disease

  2022cites this paper
• Key factors and potential drug combinations of nonalcoholic steatohepatitis: Bioinformatic analysis and experimental validation-based study.

  2021cites this paper
• NAFLD and vitamin D: Evidence for intersection of microRNA-regulated pathways

  2021influential citation
• Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients

  2021cites this paper
• The relationship between polyphenols and miRNAs: A novel therapeutic strategy for metabolic associated fatty liver disease

  2021cites this paper
• Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD

  2021cites this paper
• Targeting miRNA by Natural Products: A Novel Therapeutic Approach for Nonalcoholic Fatty Liver

  2021influential citation
• Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases

  2021cites this paper
• Mir-1, miR-122, miR-132, and miR-133 Are Related to Subclinical Aortic Atherosclerosis Associated with Metabolic Syndrome

  2021cites this paper
• A comprehensive review of long non-coding RNAs in the pathogenesis and development of non-alcoholic fatty liver disease

  2021cites this paper
• RETRACTED: MicroRNA-21 Plays Multiple Oncometabolic Roles in the Process of NAFLD-Related Hepatocellular Carcinoma via PI3K/AKT, TGF-β, and STAT3 Signaling

  2021cites this paper
• Xylo-Oligosaccharides in Prevention of Hepatic Steatosis and Adipose Tissue Inflammation: Associating Taxonomic and Metabolomic Patterns in Fecal Microbiomes with Biclustering

  2021cites this paper
• Non-coding RNAs Related to Lipid Metabolism and Non-alcoholic Fatty Liver Disease

  2021cites this paper
• Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH

  2021cites this paper
• An evolutionarily-conserved promoter allele governs HMG-CoA reductase expression in spontaneously hypertensive rat.

  2021cites this paper
• Improvement of hyperlipidemia by aerobic exercise in mice through a regulatory effect of miR-21a-5p on its target genes

  2021cites this paper
• Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis.

  2021cites this paper
• Advances on the role of miRNAs in the formation of alcoholic fatty liver

  2020cites this paper
• Critical Role of microRNA-21 in the Pathogenesis of Liver Diseases

  2020cites this paper
• MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in Huh-7 cell line

  2020cites this paper
• Non-alcoholic fatty liver disease and microRNAs expression, how it affects the development and progression of the disease.

  2020cites this paper
• Farnesoid X receptor mediates hepatic steatosis induced by PM2.5

  2020cites this paper
• Genetics and epigenetics purpose in nonalcoholic fatty liver disease

  2020cites this paper
• Cholesterol homeostasis: researching a dialogue between the brain and peripheral tissues.

  2020cites this paper
• The miR-21 potential of serving as a biomarker for liver diseases in clinical practice.

  2020cites this paper
• Modulation of hepatic miRNA expression in Atlantic salmon (Salmo salar) by family background and dietary fatty acid composition

  2020cites this paper
• Eicosapentaenoic Acid Improves Hepatic Metabolism and Reduces Inflammation Independent of Obesity in High-Fat-Fed Mice and in HepG2 Cells

  2019cites this paper
• Identification of 8‐miRNAs as biomarkers for nonalcoholic fatty liver disease

  2019cites this paper
• LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6.

  2019cites this paper
• Comprehensive bioinformatics analysis of critical lncRNAs, mRNAs and miRNAs in non-alcoholic fatty liver disease

  2019influential citation
• MicroRNAs as a Novel Tool in the Diagnosis of Liver Lipid Dysregulation and Fatty Liver Disease

  2019cites this paper
• Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-γ and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet

  2019cites this paper
• Role and mechanisms of action of microRNA-21 as regards the regulation of the WNT/β-catenin signaling pathway in the pathogenesis of non-alcoholic fatty liver disease

  2019cites this paper
• MicroRNA-495 enhances chondrocyte apoptosis, senescence and promotes the progression of osteoarthritis by targeting AKT1.

  2019cites this paper
• Emerging Circulating Biomarkers for The Diagnosis and Assessment of Treatment Responses in Patients with Hepatic Fat Accumulation, Nash and Liver Fibrosis

  2019cites this paper
• miR-155 modulates fatty acid accumulation by targeting C/EBPβ in free fatty acid-induced steatosis in HepG2 cells

  2019cites this paper
• Inhibition of miR-499-5p expression improves nonalcoholic fatty liver disease.

  2019cites this paper
• miRNAs and NAFLD: from pathophysiology to therapy

  2019cites this paper
• miR-146a improves hepatic lipid and glucose metabolism by targeting MED1

  2019cites this paper
• Role of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease

  2019cites this paper
• IFN-α-2b treatment protects against diet-induced obesity and alleviates non-alcoholic fatty liver disease in mice.

  2019cites this paper
• Investigating Pathogenic and Hepatocarcinogenic Mechanisms from Normal Liver to HCC by Constructing Genetic and Epigenetic Networks via Big Genetic and Epigenetic Data Mining and Genome-Wide NGS Data Identification

  2018cites this paper
• miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.

  2018cites this paper
• Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers

  2018cites this paper
• Critical Roles of microRNAs in the Pathogenesis of Fatty Liver: New Advances, Challenges, and Potential Directions

  2018cites this paper
• Knockout of microRNA-21 attenuates alcoholic hepatitis through the VHL/NF-κB signaling pathway in hepatic stellate cells.

  2018cites this paper